Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Braus NA et al. - Medical therapy is with mesalamine compounds, corticosteroids, immunomodulators and/or biologics that target TNF alpha signaling or alpha 4-integrin-mediated trafficking. Investigational agents include those targeted against other cytokines and costimulatory molecules or designed to promote immune regulation such as exposure to helminths which is a focus of this review.

Related Articles

Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09    Relevance Score: 83%

Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09    Relevance Score: 83%

Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09    Relevance Score: 83%

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The Lancet, 11/09/09    Relevance Score: 83%

Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history
Expert Review of Gastroenterology & Hepatology, 10/13/09    Relevance Score: 83%

Today in Gastrointestinal/Hepatic...keeping you current

Clinical factors predicting disease course in Crohn's disease
Expert Review of Clinical Immunology, 12/17/09

Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses
Immunology & Cell Biology, 12/17/09

Mucosally induced Immunological Tolerance, Regulatory T Cells and the Adjuvant Effect by Cholera Toxin B Subunit
Scandinavian Journal of Immunology, 12/16/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address